Dianthus Therapeutics, Inc. (DNTH) stock

DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30

$92.48+3.18 (+3.56%)

Close on Nov 12, 2026Market cap $5.17BP/E –Yield 0.00%

Dianthus Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Dianthus Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Dianthus Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-67 reverse split on Nov 9, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DNTH.

Revenue growth-67.3% · median 0.2%

Operating margin-11592.7% · median -6116.0%

Net margin-9927.5% · median -5712.3%

Advertisement
300 × 250

See a number that looks wrong?